Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Mylan

Share:
Related MYL
Who's The Next Big Pharma Acquisition?
Benzinga's M&A Chatter for Wednesday May 27, 2015
Teva Settles Provigil Drug Delay Charge with FTC for $1.2B - Analyst Blog (Zacks)

In a report published Monday, Bank of America Merrill Lynch reiterated its Buy rating on Mylan (NASDAQ: MYL), and slightly raised its price target from $29.00 to $30.00.

BofA Merrill Lynch noted, “With significant acquisitions in '07, MYL transformed itself from a US-only, generic-only story into a global, diversified, vertically-integrated one. Though management's original assumptions for Dey (brands) proved optimistic, we are encouraged by revenue trends in generics and potential for margin improvements. Integration risks and high debt level are key risks, but as the only large, liquid, global generic alternative to Teva, we see MYL as a higher risk, higher reward name.”

Mylan closed on Friday at $27.97.

Latest Ratings for MYL

DateFirmActionFromTo
Apr 2015CRT CapitalMaintainsBuy
Apr 2015BMO CapitalUpgradesUnderperformMarket Perform
Apr 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (MYL)

Around the Web, We're Loving...